Ratings PT Chandra Asri Pacific Tbk OTC Markets

Equities

PTPIF

ID1000090301

Market Closed - OTC Markets Other stock markets 09:30:01 2024-06-12 am EDT			5-day change	1st Jan Change
0.5061 ^USD	+12.47%		-.--%	+66.04%

May. 10	Chandra Asri purchase of Shell Singapore refinery brings scale, risk	RE
May. 09	Chandra Asri purchase of Shell Singapore refinery brings scale, risk	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company has insufficient levels of profitability.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1362.69 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Commodity Chemicals

	1st Jan change	Capi.	ESG Refinitiv
PT CHANDRA ASRI PACIFIC TBK	+66.04%	52.55B	-
AIR LIQUIDE	+1.97%	102B	A-
SABIC	-5.63%	62.47B	A-
WANHUA CHEMICAL GROUP CO., LTD.	+6.44%	35.34B	B
LYONDELLBASELL INDUSTRIES N.V.	+2.82%	31.83B	A-
WESTLAKE CORPORATION	+6.73%	19.21B	B-
NINGXIA BAOFENG ENERGY GROUP CO., LTD.	+18.21%	17.58B	C+
HENGLI PETROCHEMICAL CO.,LTD.	+8.81%	13.89B	B-
SOLAR INDUSTRIES INDIA LIMITED	+75.12%	12.76B	B-
RONGSHENG PETROCHEMICAL CO., LTD.	-7.05%	12.68B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes